C12N 2760/18141
Use of virus, viral particle or viral elements as a vector
C12N2760/18141 (Use of virus, viral particle or viral elements as a vector) appears on 46 US grants and 88 published applications in this corpus.
Search patents in C12N- Granted patents
- 46
- Published applications
- 88
- Assignees
- 40
- Inventors
- 176
- Latest grant
- 28 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 2 | 2 |
| 2004 | 1 | 3 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 1 | 0 |
| 2008 | 2 | 1 |
| 2009 | 1 | 4 |
| 2010 | 0 | 5 |
| 2011 | 1 | 4 |
| 2012 | 1 | 6 |
| 2013 | 2 | 1 |
| 2014 | 2 | 9 |
| 2015 | 4 | 3 |
| 2016 | 3 | 4 |
| 2017 | 3 | 5 |
| 2018 | 3 | 5 |
| 2019 | 7 | 2 |
| 2020 | 0 | 4 |
| 2021 | 2 | 3 |
| 2022 | 6 | 8 |
| 2023 | 0 | 7 |
| 2024 | 2 | 2 |
| 2025 | 2 | 7 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/18143Viral genome or elements thereof as genetic vectorIndexing code44
- C12N 2760/18144Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code2
- C12N 2760/18145Special targeting system for viral vectorsIndexing code1
- C12N 2760/18142Virus or viral particle as vehicleIndexing code0
Recent patents
- Recombinant vaccine against COVID-19 based on a paramyxovirus viral vector28 Apr 2026US 12,611,454 B2Icahn School of Medicine at Mount Sinai
- Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease19 Aug 2025US 12,391,957 B2Icahn School of Medicine at Mount Sinai
- Recombinant vaccine against Marek's disease and Newcastle disease25 Mar 2025US 12,258,372 B2The United States of America as represented by the Secretary of Agriculture
- Newcastle disease viruses and uses thereof23 Jul 2024US 12,042,534 B2Icahn School of Medicine at Mount Sinai
- Oncolytic virus for colorectal cancer treatment using colorectal cancer cell-specific infectious newcastle disease virus and composition for colorectal cancer treatment using same30 Jan 2024US 11,884,931 B2Libentech Co., Ltd.
- Apmv and uses thereof for the treatment of cancer30 Jul 2026US 2026/0216266 A1Icahn School of Medicine at Mount Sinai
- Virus attenuation30 Apr 2026US 2026/0115273 A1University of Lancaster
- Recombinant vaccine against covid-19 to produce cellular response in individuals with pre-existing immunity11 Dec 2025US 2025/0375515 A1Consejo Nacional De Humanidades, Ciencias Y TecnologíAS
- Recombinant newcastle disease virus expressing lassa virus gp or np, and uses thereof7 Aug 2025US 2025/0250304 A1Bernhard-Nocht-Institut FüR Tropenmedizin
- Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant17 Jul 2025US 2025/0228929 A1Icahn School of Medicine at Mount Sinai
Most cited
By later US patents
- Helper-free rescue of recombinant negative strand RNA viruses97US 6,544,785 B1Mount Sinai School of Medicine of New York University · 2003
- Helper-free rescue of recombinant negative strand RNA virus78US 6,649,372 B1Mount Sinai School of Medicine of New York University · 2003
- Helper-free rescue of recombinant negative strand RNA virus30US 7,384,774 B2Mount Sinai School of Medicine of New York University · 2008
- Newcastle disease virus infectious clones, vaccines and diagnostic assays24US 6,719,979 B2ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V. · 2004
- Influenza virus vaccines and uses thereof23US 9,051,359 B2Icahn School of Medicine at Mount Sinai · 2015